chlorzoxazone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
626 95-25-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorzoxazone
  • 5-Chlorobenzoxazolidone
  • chlorzoxazon
  • chloroxazone
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
  • Molecular weight: 169.56
  • Formula: C7H4ClNO2
  • CLOGP: 1.87
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -1.76
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 196.38 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 1958 FDA JANSSEN R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 101.46 24.89 35 1381 24131 46660515
Intentional overdose 82.92 24.89 40 1376 64904 46619742
Completed suicide 71.53 24.89 48 1368 145872 46538774
Depressed level of consciousness 31.53 24.89 19 1397 47550 46637096
Pulmonary renal syndrome 31.37 24.89 6 1410 386 46684260
Stevens-Johnson syndrome 28.58 24.89 14 1402 23283 46661363

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Secondary adrenocortical insufficiency 87.22 44.85 14 292 1003 29951169
Spinal column injury 52.65 44.85 8 298 397 29951775

Pharmacologic Action:

SourceCodeDescription
ATC M03BB03 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB53 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB73 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
FDA PE N0000175730 Centrally-mediated Muscle Relaxation
FDA EPC N0000175737 Muscle Relaxant
CHEBI has role CHEBI:35717 sedatives
CHEBI has role CHEBI:51371 muscle relaxants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Spasticity indication 221360009
Muscle Spasm with Pain indication
Alcoholism contraindication 7200002
Hepatic failure contraindication 59927004
Poisoning by acetaminophen contraindication 70273001
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.22 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Calcium-activated potassium channel subunit alpha-1 Ion channel OPENER EC50 4.52 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel ACTIVATOR EC50 4 IUPHAR
Nitric oxide synthase, inducible Enzyme IC50 4.85 CHEMBL
Nitric oxide synthase, brain Enzyme IC50 4.30 CHEMBL
Nitric oxide synthase, endothelial Enzyme IC50 5.06 CHEMBL
Nitric oxide synthase, brain Enzyme IC50 5.55 DRUG MATRIX
Small conductance calcium-activated potassium channel protein 2 Unclassified ACTIVATOR EC50 4.10 IUPHAR

External reference:

IDSource
4017882 VUID
N0000146235 NUI
D00771 KEGG_DRUG
4017882 VANDF
C0008296 UMLSCUI
CHEBI:3655 CHEBI
CLW PDB_CHEM_ID
2733 PUBCHEM_CID
CHEMBL1371 ChEMBL_ID
DB00356 DRUGBANK_ID
D002753 MESH_DESCRIPTOR_UI
2322 IUPHAR_LIGAND_ID
748 INN_ID
H0DE420U8G UNII
2410 RXNORM
4369 MMSL
4433 MMSL
d00962 MMSL
001671 NDDF
400361007 SNOMEDCT_US
44908000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0254-2005 TABLET 750 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0254-2053 TABLET 375 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2520 TABLET 500 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-717 TABLET 375 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-718 TABLET 750 mg ORAL ANDA 12 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16590-478 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 21695-569 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 33261-021 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42254-076 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-425 TABLET 375 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-426 TABLET 500 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-427 TABLET 500 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-428 TABLET 750 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 45865-434 TABLET 500 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 46672-117 TABLET 750 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 46672-118 TABLET 375 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 46672-860 TABLET 250 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 49999-044 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0315 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0316 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 51862-338 TABLET 375 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 51862-339 TABLET 500 mg ORAL ANDA 14 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 51862-340 TABLET 750 mg ORAL ANDA 14 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 52817-230 TABLET 375 mg ORAL ANDA 11 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 52817-231 TABLET 750 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 53002-5760 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 54868-0735 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 55045-1594 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 55289-633 TABLET 500 mg ORAL ANDA 12 sections
Lorzone HUMAN PRESCRIPTION DRUG LABEL 1 55700-517 TABLET 375 mg ORAL ANDA 12 sections